XPENG INC - ADR (XPEV) Fundamental Analysis & Valuation

NYSE:XPEV • US98422D1054

Current stock price

16.72 USD
-0.21 (-1.24%)
At close:
16.6 USD
-0.12 (-0.72%)
After Hours:

This XPEV fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. XPEV Profitability Analysis

1.1 Basic Checks

  • In the past year XPEV has reported negative net income.
  • In the past 5 years XPEV always reported negative net income.
  • In the past 5 years XPEV reported 4 times negative operating cash flow.
XPEV Yearly Net Income VS EBIT VS OCF VS FCFXPEV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 0 -2B -4B -6B -8B -10B

1.2 Ratios

  • The Return On Assets of XPEV (-1.10%) is better than 71.43% of its industry peers.
  • Looking at the Return On Equity, with a value of -3.75%, XPEV is in the better half of the industry, outperforming 68.57% of the companies in the same industry.
Industry RankSector Rank
ROA -1.1%
ROE -3.75%
ROIC N/A
ROA(3y)-6.81%
ROA(5y)-8.12%
ROE(3y)-16.94%
ROE(5y)-17.43%
ROIC(3y)N/A
ROIC(5y)N/A
XPEV Yearly ROA, ROE, ROICXPEV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 2025 -50 -100 -150

1.3 Margins

  • XPEV's Gross Margin of 19.35% is amongst the best of the industry. XPEV outperforms 82.86% of its industry peers.
  • In the last couple of years the Gross Margin of XPEV has grown nicely.
  • The Profit Margin and Operating Margin are not available for XPEV so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 19.35%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y16.02%
GM growth 5Y21.18%
XPEV Yearly Profit, Operating, Gross MarginsXPEV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 2025 0 -5K -10K -15K -20K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. XPEV Health Analysis

2.1 Basic Checks

  • XPEV does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for XPEV has been increased compared to 1 year ago.
  • Compared to 5 years ago, XPEV has more shares outstanding
  • XPEV has a worse debt/assets ratio than last year.
XPEV Yearly Shares OutstandingXPEV Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M
XPEV Yearly Total Debt VS Total AssetsXPEV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 2025 20B 40B 60B 80B 100B

2.2 Solvency

  • XPEV has an Altman-Z score of 1.07. This is a bad value and indicates that XPEV is not financially healthy and even has some risk of bankruptcy.
  • XPEV has a better Altman-Z score (1.07) than 65.71% of its industry peers.
  • XPEV has a Debt/Equity ratio of 1.01. This is a high value indicating a heavy dependency on external financing.
  • XPEV has a Debt to Equity ratio of 1.01. This is in the lower half of the industry: XPEV underperforms 60.00% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.01
Debt/FCF N/A
Altman-Z 1.07
ROIC/WACCN/A
WACC8.11%
XPEV Yearly LT Debt VS Equity VS FCFXPEV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 0 10B -10B 20B 30B 40B

2.3 Liquidity

  • XPEV has a Current Ratio of 1.09. This is a normal value and indicates that XPEV is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 1.09, XPEV is in line with its industry, outperforming 42.86% of the companies in the same industry.
  • A Quick Ratio of 0.91 indicates that XPEV may have some problems paying its short term obligations.
  • The Quick ratio of XPEV (0.91) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 1.09
Quick Ratio 0.91
XPEV Yearly Current Assets VS Current LiabilitesXPEV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 2025 20B 40B 60B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. XPEV Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 80.36% over the past year.
  • XPEV shows a strong growth in Revenue. In the last year, the Revenue has grown by 87.73%.
  • XPEV shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 67.35% yearly.
EPS 1Y (TTM)80.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%128.57%
Revenue 1Y (TTM)87.73%
Revenue growth 3Y41.89%
Revenue growth 5Y67.35%
Sales Q2Q%38.18%

3.2 Future

  • The Earnings Per Share is expected to grow by 47.31% on average over the next years. This is a very strong growth
  • The Revenue is expected to grow by 17.61% on average over the next years. This is quite good.
EPS Next Y158.21%
EPS Next 2Y120.94%
EPS Next 3Y75.22%
EPS Next 5Y47.31%
Revenue Next Year31.3%
Revenue Next 2Y28.02%
Revenue Next 3Y21.67%
Revenue Next 5Y17.61%

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
XPEV Yearly Revenue VS EstimatesXPEV Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 50B 100B 150B 200B
XPEV Yearly EPS VS EstimatesXPEV Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 5 -5 -10

More info and screens

Find the best growth stocksShow best growing peers

2

4. XPEV Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for XPEV. In the last year negative earnings were reported.
  • XPEV is valuated quite expensively with a Price/Forward Earnings ratio of 165.48.
  • Based on the Price/Forward Earnings ratio, XPEV is valued a bit cheaper than the industry average as 65.71% of the companies are valued more expensively.
  • XPEV's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 22.10.
Industry RankSector Rank
PE N/A
Fwd PE 165.48
XPEV Price Earnings VS Forward Price EarningsXPEV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50 100 150

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
XPEV Per share dataXPEV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8 10

4.3 Compensation for Growth

  • XPEV's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
  • A more expensive valuation may be justified as XPEV's earnings are expected to grow with 75.22% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y120.94%
EPS Next 3Y75.22%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. XPEV Dividend Analysis

5.1 Amount

  • No dividends for XPEV!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

XPEV Fundamentals: All Metrics, Ratios and Statistics

XPENG INC - ADR

NYSE:XPEV (3/30/2026, 8:04:00 PM)

After market: 16.6 -0.12 (-0.72%)

16.72

-0.21 (-1.24%)

Chartmill FA Rating
GICS IndustryGroupAutomobiles & Components
GICS IndustryAutomobiles
Earnings (Last)03-20
Earnings (Next)05-21
Inst Owners10.88%
Inst Owner Change-8.62%
Ins Owners0.25%
Ins Owner Change0%
Market Cap15.95B
Revenue(TTM)76.72B
Net Income(TTM)-1.14B
Analysts80.59
Price Target24.26 (45.1%)
Short Float %11.65%
Short Ratio6.29
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)111.64%
Min EPS beat(2)2.77%
Max EPS beat(2)220.52%
EPS beat(4)4
Avg EPS beat(4)76.48%
Min EPS beat(4)2.77%
Max EPS beat(4)220.52%
EPS beat(8)5
Avg EPS beat(8)39.55%
EPS beat(12)6
Avg EPS beat(12)23.68%
EPS beat(16)7
Avg EPS beat(16)13.65%
Revenue beat(2)0
Avg Revenue beat(2)-1.34%
Min Revenue beat(2)-1.42%
Max Revenue beat(2)-1.26%
Revenue beat(4)1
Avg Revenue beat(4)-0.85%
Min Revenue beat(4)-3.26%
Max Revenue beat(4)2.52%
Revenue beat(8)2
Avg Revenue beat(8)-2.24%
Revenue beat(12)2
Avg Revenue beat(12)-4.19%
Revenue beat(16)3
Avg Revenue beat(16)-4.37%
PT rev (1m)-6.49%
PT rev (3m)-12.81%
EPS NQ rev (1m)-100.96%
EPS NQ rev (3m)-358.81%
EPS NY rev (1m)-54.01%
EPS NY rev (3m)-56.18%
Revenue NQ rev (1m)-17.53%
Revenue NQ rev (3m)-33.38%
Revenue NY rev (1m)-3.24%
Revenue NY rev (3m)-6.33%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 165.48
P/S 1.44
P/FCF N/A
P/OCF N/A
P/B 3.63
P/tB 4.22
EV/EBITDA N/A
EPS(TTM)-0.17
EYN/A
EPS(NY)0.1
Fwd EY0.6%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS11.63
BVpS4.6
TBVpS3.96
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -1.1%
ROE -3.75%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 19.35%
FCFM N/A
ROA(3y)-6.81%
ROA(5y)-8.12%
ROE(3y)-16.94%
ROE(5y)-17.43%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y16.02%
GM growth 5Y21.18%
F-ScoreN/A
Asset Turnover0.74
Health
Industry RankSector Rank
Debt/Equity 1.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.09
Quick Ratio 0.91
Altman-Z 1.07
F-ScoreN/A
WACC8.11%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)80.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%128.57%
EPS Next Y158.21%
EPS Next 2Y120.94%
EPS Next 3Y75.22%
EPS Next 5Y47.31%
Revenue 1Y (TTM)87.73%
Revenue growth 3Y41.89%
Revenue growth 5Y67.35%
Sales Q2Q%38.18%
Revenue Next Year31.3%
Revenue Next 2Y28.02%
Revenue Next 3Y21.67%
Revenue Next 5Y17.61%
EBIT growth 1Y62.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year200.41%
EBIT Next 3Y77.93%
EBIT Next 5Y45.9%
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

XPENG INC - ADR / XPEV Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for XPENG INC - ADR?

ChartMill assigns a fundamental rating of 2 / 10 to XPEV.


What is the valuation status for XPEV stock?

ChartMill assigns a valuation rating of 2 / 10 to XPENG INC - ADR (XPEV). This can be considered as Overvalued.


How profitable is XPENG INC - ADR (XPEV) stock?

XPENG INC - ADR (XPEV) has a profitability rating of 2 / 10.